MiNK Therapeutics CSO Marc Van Dijk transitions to advisory roles effective Nov 15

MiNK Therapeutics, Inc.

Dr. Marc Van Dijk leaves Chief Scientific Officer role, becomes Scientific Advisory Board Member and Strategic Consultant.
Transition effective November 15, 2024; Van Dijk to continue supporting programs and collaborations.
No replacement for CSO announced; advisory roles indicate retained expertise.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Dr. Marc Van Dijk

Chief Scientific Officer

INKT · MiNK Therapeutics, Inc.

Effective: 2024-11-15
Filed: October 18, 2024, 7:59 PM ET

Dr. Marc Van Dijk will transition from his role as Chief Scientific Officer and assume the positions of Scientific Advisory Board Member and Strategic Consultant.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Marc Van Dijk changed role as Chief Scientific Officer at MiNK Therapeutics, Inc..

Action: transitioned from
Role: Chief Scientific Officer

Exact text from the filing

Dr. Marc Van Dijk will transition from his role as Chief Scientific Officer and assume the positions of Scientific Advisory Board Member and Strategic Consultant.

View on SEC.gov

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-115596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.